Coherus BioSciences sells YUSIMRY biosimilar to HKF for $40M cash, focusing on oncology.
Coherus BioSciences, Inc. (CHRS) announced divestiture of YUSIMRY (adalimumab-aqvh), a biosimilar to HUMIRA, to Hong Kong King-Friend Industrial Co. Ltd (HKF) for $40M upfront cash. HKF's subsidiary, Meitheal Pharmaceuticals, will continue to commercialize YUSIMRY in the U.S. The sale aligns with Coherus' strategic focus on oncology, with proceeds aimed at bolstering cash position, promoting oncology growth, and efficiently allocating resources.
June 27, 2024
5 Articles